Skip to main content
. 2020 May 18;11:2040622320922023. doi: 10.1177/2040622320922023

Figure 5.

Figure 5.

Two-year all-cause mortality related to 5MGS and MELDNa-5MGS. The vertical bars show the percentages of patients (blue: all patients; orange: deceased patients), scaled on the y-axis, and corresponded to the indicated intervals of 5MGS (A) and MELDNa-5MGS (B) on the x-axis. The trend was statistically significant for 5MGS (p = 0.003) and MELDNa-5MGS (p < 0.001) using the Cochran-Armitage test.

MELD-Na, model for end-stage liver disease-sodium; MELDNa-5MGS, MELDNa-5-m gait speed.